Noxopharm Ltd (ASX: NOX) Share Price and News

Mr Bart was appointed the Managing Director of Textile Industries Australia In 1985,. The Group employed over 1,200 people and distributed product to many countries worldwide. The Company manufactured and distributed the majority of bed linen in Australia under brands like Sheridan and ACTIL. In 1989, Mr Bart established and chairs a number of private companies under the umbrella of the Bart Group which covered hotels, retail, commercial and residential land development and technologies which still continue to operate. The Group today employs in excess of 1,000 people and is active in many local and overseas markets. In 2013, Mr Bart became Director and majority shareholder of Immunovative Therapies Limited, a private Israeli company involved in the manufacture of vaccines for the treatment of certain forms of cancer. The Company has undertaken trials in both collateral and liver cancers. He is a member of Risk Committee.

Mr Marks has over 35 years of experience in corporate advisory and investment banking. Over the course of his career, he has specialised in capital raising IPO's, cross border capital raisings, M&A transactions, corporate underwriting and venture capital transactions for companies based in Australia, the US and Israel. He has been involved in a range of transactions with a focus in the life-sciences, biotechnology, medical technology and high tech as well as the mining sector. Peter has served as both an Executive and Non-Executive Director of a number of different entities, many of which have been listed on the ASX, Nasdaq and AIM markets. He is Chair of Risk Committee.

Mr Patkin brings market knowledge, thorough research and years of experience in investment markets and business consulting. As a financial and investment advisor, Boris has an understanding of industry trends and has insight into domestic and international markets. He specialises in the reconstruction of companies, investments and in international trade and is also a business consultant in the medical and disruptive technology arena. He is currently a member of MeSAFAA and is a senior advisor with Morgans Financial Ltd. He is also non-executive chairman of Ausmon Resources Ltd - since 2014. He is member of Risk Committee.

Dr Mautner has more than 20 years of experience in global pharmaceutical organisations, including operational, medical and scientific advisory roles across multiple therapeutic areas. During her career she held senior positions at global pharmaceutical companies like MSD (Merck), Bayer and Amgen in Germany as well as Australia.

-

-